1. Home
  2. PXED vs TBPH Comparison

PXED vs TBPH Comparison

Compare PXED & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PXED

Phoenix Education Partners Inc.

N/A

Current Price

$32.49

Market Cap

1.2B

Sector

Real Estate

ML Signal

N/A

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$17.89

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PXED
TBPH
Founded
1976
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
993.7M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
PXED
TBPH
Price
$32.49
$17.89
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$45.00
$27.80
AVG Volume (30 Days)
107.6K
535.4K
Earning Date
11-20-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.51
0.58
Revenue
$1,007,192,000.00
$80,327,000.00
Revenue This Year
$4.15
$70.78
Revenue Next Year
$4.77
N/A
P/E Ratio
$9.27
$31.31
Revenue Growth
6.02
27.12
52 Week Low
$23.52
$7.90
52 Week High
$47.08
$20.33

Technical Indicators

Market Signals
Indicator
PXED
TBPH
Relative Strength Index (RSI) N/A 51.95
Support Level N/A $17.25
Resistance Level N/A $20.32
Average True Range (ATR) 0.00 0.72
MACD 0.00 -0.27
Stochastic Oscillator 0.00 21.01

Price Performance

Historical Comparison
PXED
TBPH

About PXED Phoenix Education Partners Inc.

Phoenix Education Partners Inc is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. It is one of the online education providers and a pioneer in its field, the company benefits from the dynamic interplay between technological innovation, education, employment and economic trends. It is focused on delivering a personalized, career-relevant and affordable education to its students through its flexible learning model, skills-aligned curriculum and accessible tuition costs.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: